🇺🇸 FDA
Patent

US 7374752

Reovirus for the treatment of cellular proliferative disorders

granted A61KA61K35/765A61K9/0019

Quick answer

US patent 7374752 (Reovirus for the treatment of cellular proliferative disorders) held by ONCOLYTICS BIOTECH INC. expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ONCOLYTICS BIOTECH INC.
Grant date
Tue May 20 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K35/765, A61K9/0019, A61P, A61P31/12